Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study

Clinical Lymphoma, Myeloma and Leukemia - Tập 22 - Trang e405-e413 - 2022
Virginia Abello1, William Armando Mantilla2, Henry Idrobo3, Claudia Lucia Sossa4, Luis Antonio Salazar4, Angela Pena4, Juan Manuel Herrera5, Paola Guerrero5, Daniel Espinosa6, Guillermo Enrique Quintero-Vega7, Isabel Munevar8, Kenny Galvez9, Alicia Henao10, Rigoberto Gómez11, Jose Domingo Saavedra12, Lina María Gaviria13, Mónica Osuna14, María Victoria Mateos15
1Fundación Universitaria de Ciencias de la Salud, Hospital de San José, Clínica del Country, Bogotá, Colombia
2Fundación Cardioinfantil-Instituto de Cardiología. Bogotá, Colombia
3Universidad del Valle, Centro Médico Julián Coronel, Calí, Colombia
4Universidad Autónoma de Bucaramanga, Clínica Foscal, Centro de hematología PROTEHOS, Bucaramanga, Colombia
5Clínica imbanaco Quiron Salud, Cali-Colombia
6Fundación Universitaria de Ciencias de la Salud, Hospital de San José, Bogotá, Colombia
7Universidad de los Andes, Fundación Santa Fe de Bogotá, Servicios Médicos de Hematología y Cardiología SAS, Bogotá, Colombia
8Fundación Cardioinfantil, Hospital Militar, Bogotá, Colombia
9Hospital Pablo Tobón Uribe, Medellín, Colombia
10Clínica Astorga, Medellín, Colombia
11HematoOncologos SA, Cali, Colombia
12Clínica Vida, Medellín, Colombia
13Hospital Universitario San Vicente Fundación, Medellín, Colombia
14Clínica los Nogales, Bogotá, Colombia
15Hospital Universitario de Salamanca, Centro de Investigación del Cáncer de Salamanca, Salamanca, España

Tài liệu tham khảo

Vargas-Serafin, 2021, Impact of Socioeconomic Characteristics and Comorbidities on Therapy Initiation and Outcomes of Newly Diagnosed Multiple Myeloma: Real-World Data From a Resource-Constrained Setting, Clin Lymphoma Myeloma Leuk, 21, 182, 10.1016/j.clml.2020.11.020

2020

Cifras y estimaciones de cáncer en el mundo Globocan e IARC. The Global Cancer Observatory 2018 [Internet]. 2018.

Estimated number of incident cases from 2018 to 2040, all cancers, both sexes, all ages Available at: https://gco.iarc.fr/tomorrow/graphic-bar? type=1&type_sex=0&mode=population&sex=0&populations=170&cancers=39&age_group=value&apc_male=0&apc_female=0&single_unit=500000&print=0#collapse-group-0-1: International Agency for Research of Cancer; 2020

DANE. Causas de muerte en el 2018 Available at: http://systema74.dane.gov.co/bincol/RpWebEngine.exe/Portal?BASE=DEFOC2018〈=esp:DANE; 2018

WHO classification of Tumors of Haematopoietic and Lymphoid Tissues 2017.

Arias, 2013, Registros poblacionales de cáncer: avances en Colombia, Chile y Brasil, Rev Fac Nac Salud Pública, 31, 128

Cancer IAfRi. Globocan Colombia 2020 Available at: https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-sheets.pdf: Organización Mundial de la Salud; 2020

Fondo Colombiano de Enfermedades de Alto Costo CdACC. Situación del cáncer en la pobla ción adulta atendida en el SGSSS de Colombia 2019. 2019.

Hungria, 2017, Observational study of multiple myeloma in Latin America, Ann Hematol, 96, 65, 10.1007/s00277-016-2866-9

Rajkumar, 2014, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, The Lancet Oncology, 15, E538, 10.1016/S1470-2045(14)70442-5

Greipp, 2005, International staging system for multiple myeloma, J Clin Oncol, 23, 3412, 10.1200/JCO.2005.04.242

Belotti, 2020, Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years, Am J Hematol, 95, 759, 10.1002/ajh.25797

Martínez, 2020, Multiple Myeloma Mortality Incidence Prevalence of Disease - Mmy Mind Study, Blood, 136, 10, 10.1182/blood-2020-142376

Moreau, 2016, VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial, Blood, 127, 2569, 10.1182/blood-2016-01-693580

Mai, 2015, Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma, Leukemia, 29, 1721, 10.1038/leu.2015.80

Kariyawasan, 2007, Multiple myeloma: Causes and consequences of delay in diagnosis, QJM, 100, 635, 10.1093/qjmed/hcm077

Curado, 2018, Epidemiology of multiple myeloma in 17 Latin American countries: An update, Cancer Medicine, 7, 2101, 10.1002/cam4.1347

Maiolino, 2018, Unmet needs in multiple myeloma in Brazil from physicians’ perspective – barriers in quality of life and disease management, Jornal Brasileiro de Economia da Saúde, 10, 165, 10.21115/JBES.v10.n2.p165-171

Ghalehsari, 2019, An institutional retrospective study on recognizing the delay in multiple myeloma diagnosis, Blood, 134, 3430, 10.1182/blood-2019-127625

Koshiaris, 2019, Methods for reducing delays in the diagnosis of multiple myeloma, International Journal of Hematologic Oncology, 8, 10.2217/ijh-2018-0014

Chng, 2014, IMWG consensus on risk stratification in multiple myeloma, Leukemia, 28, 269, 10.1038/leu.2013.247

Palumbo, 2015, Revised international staging system for multiple myeloma: a report from international myeloma working group, J Clin Oncol, 33, 2863, 10.1200/JCO.2015.61.2267

Cazaubiel, 2020, Risk and Response-Adapted Treatment in Multiple Myeloma, Cancers (Basel), 12, 3497, 10.3390/cancers12123497

Attal, 1997, Standard therapy versus autologous transplantation in multiple myeloma, Hematol Oncol Clin North Am, 11, 133, 10.1016/S0889-8588(05)70419-6

Child, 2003, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma, N Engl J Med, 348, 1875, 10.1056/NEJMoa022340

Palumbo, 2014, Autologous transplantation and maintenance therapy in multiple myeloma, N Engl J Med, 371, 895, 10.1056/NEJMoa1402888

Attal, 2017, Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma, N Engl J Med, 376, 1311, 10.1056/NEJMoa1611750

Gay, 2017, Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis, Leukemia, 31, 1727, 10.1038/leu.2016.381

Riva, 2015, Real-World Data on Multiple Myeloma: A Prospective National Registry in Uruguay, Blood, 126, 5614, 10.1182/blood.V126.23.5614.5614

Mohty, 2018, Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study, Clin Lymphoma Myeloma Leuk, 18, e401, 10.1016/j.clml.2018.06.018

Jaimovich, 2017, Latin America: the next region for haematopoietic transplant progress, Bone Marrow Transplant, 52, 671, 10.1038/bmt.2016.361

de Moraes Hungria, 2020, Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016, Br J Haematol, 188, 383, 10.1111/bjh.16124

Verelst, 2018, Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS), Hemasphere, 2, e45, 10.1097/HS9.0000000000000045

Abello-Polo, 2020, ACHO (Asociación Colombiana de Hematología y Oncología), RENEHOC researchers. Impact of Insurance Differences in Outcomes in Colombian Patients with Chronic Myeloid Leukemia (CML), Clynical Lymphoma, Myeloma and Leukemia., 20, S240, 10.1016/S2152-2650(20)30827-2